[go: up one dir, main page]

PE20121544A1 - Vacuna de pcsk9 - Google Patents

Vacuna de pcsk9

Info

Publication number
PE20121544A1
PE20121544A1 PE2012000286A PE2012000286A PE20121544A1 PE 20121544 A1 PE20121544 A1 PE 20121544A1 PE 2012000286 A PE2012000286 A PE 2012000286A PE 2012000286 A PE2012000286 A PE 2012000286A PE 20121544 A1 PE20121544 A1 PE 20121544A1
Authority
PE
Peru
Prior art keywords
pcsk9
refers
antigenic peptide
ldl
pcsk9 vaccine
Prior art date
Application number
PE2012000286A
Other languages
English (en)
Inventor
Brian Robert Champion
Leonard Gabriel Contillo Jr
Michael Dale Eisenbraun
James Downey Fraser
Julie Jia Li Hawkins
James Richard Merson
Brian Gregory Pierce
Xiayang Qiu
Jakir Hussain Ullah
David Michael Wyatt
Original Assignee
Pfizer Vaccines Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Vaccines Llc filed Critical Pfizer Vaccines Llc
Publication of PE20121544A1 publication Critical patent/PE20121544A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/005—Trypanosoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21061—Kexin (3.4.21.61), i.e. proprotein convertase subtilisin/kexin type 9

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

SE REFIERE A UN INMUNOGENO QUE COMPRENDE i) UN PEPTIDO ANTIGENICO DE PCSK9 O UNA VARIANTE FUNCIONALMENTE ACTIVA DEL MISMO QUE INTERACCIONA CON EL DOMINIO EGF-A DEL RECEPTOR LDL UNIDO A ii) UN VEHICULO INMUNOGENICO TAL COMO CRM197 O VLP DE Qbeta; EN DONDE EL PEPTIDO ANTIGENICO DE PCSK9 COMPRENDE ENTRE 4 Y 20 AMINOACIDOS Y SE SELECCIONA ENTRE LAS SEC ID Nº 19, 56, 63, 109, 153, 165, 184, 186, 187, 188, 308, 309, 310, 311, 312, 332, 421, 422, 423, 424, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION. DICHO INMUNOGENO REDUCE EL NIVEL DE COLESTEROL-LDL EN AL MENOS 10% SIENDO UTIL EN EL TRATAMIENTO DE HIPERLIPIDEMIA, HIPERCOLESTEROLEMIA, ATEROSCLEROSIS
PE2012000286A 2009-09-03 2010-08-23 Vacuna de pcsk9 PE20121544A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23954109P 2009-09-03 2009-09-03

Publications (1)

Publication Number Publication Date
PE20121544A1 true PE20121544A1 (es) 2012-12-02

Family

ID=43413463

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2016002226A PE20161551A1 (es) 2009-09-03 2010-08-23 Vacuna de pcsk9
PE2012000286A PE20121544A1 (es) 2009-09-03 2010-08-23 Vacuna de pcsk9
PE2016002242A PE20161560A1 (es) 2009-09-03 2010-08-23 Vacuna de pcsk9

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2016002226A PE20161551A1 (es) 2009-09-03 2010-08-23 Vacuna de pcsk9

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2016002242A PE20161560A1 (es) 2009-09-03 2010-08-23 Vacuna de pcsk9

Country Status (29)

Country Link
US (4) US8889144B2 (es)
EP (3) EP2865752A1 (es)
JP (5) JP2013503623A (es)
KR (3) KR101660578B1 (es)
CN (3) CN104548089B (es)
AR (2) AR078247A1 (es)
AU (1) AU2010290931B2 (es)
BR (1) BR112012004807A2 (es)
CA (2) CA2771770A1 (es)
CO (1) CO6501190A2 (es)
DK (1) DK2473605T3 (es)
ES (1) ES2670576T3 (es)
HU (1) HUE037416T2 (es)
IL (2) IL218229A (es)
MX (1) MX2012002639A (es)
MY (1) MY163512A (es)
NO (1) NO2473605T3 (es)
NZ (3) NZ620441A (es)
PE (3) PE20161551A1 (es)
PH (2) PH12016500004A1 (es)
PL (1) PL2473605T3 (es)
PT (1) PT2473605T (es)
RU (2) RU2538162C2 (es)
SA (3) SA114350179B1 (es)
SG (3) SG10201401515YA (es)
SI (1) SI2473605T1 (es)
TR (1) TR201808222T4 (es)
TW (1) TWI400085B (es)
WO (1) WO2011027257A2 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2735171C (en) 2008-08-29 2023-10-03 Oral Health Australia Pty Ltd Prevention, treatment and diagnosis of p.gingivalis infection
WO2010067262A1 (en) 2008-12-09 2010-06-17 Pfizer Inc. Immunostimulatory oligonucleotides
US8552165B2 (en) * 2008-12-09 2013-10-08 Heather Davis Immunostimulatory oligonucleotides
GB201005005D0 (en) * 2010-03-25 2010-05-12 Angeletti P Ist Richerche Bio New vaccine
US20140004142A1 (en) * 2011-03-02 2014-01-02 Pfizer Inc. Pcsk9 vaccine
EP2532359A1 (en) 2011-06-10 2012-12-12 Affiris AG CETP fragments
HUE028583T2 (en) * 2011-09-13 2016-12-28 Affiris Ag PCSK9 vaccine
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
EP2703483A1 (en) * 2012-08-29 2014-03-05 Affiris AG PCSK9 peptide vaccine
WO2014060383A1 (en) * 2012-10-17 2014-04-24 Glaxosmithkline Biologicals S.A. Immunogenic composition comprising 1 or more streptococcus pneumoniae capsular saccharide conjugates and a protein component comprising protein e and/or pila fromhaemophilus influenzae.
US10058630B2 (en) * 2012-10-22 2018-08-28 Concievalve, Llc Methods for inhibiting stenosis, obstruction, or calcification of a stented heart valve or bioprosthesis
US20150274784A1 (en) * 2012-11-07 2015-10-01 Vacplanta Limted Production of an Immunogen Using a Plant Virus
US10117923B2 (en) 2012-11-07 2018-11-06 Vacplanta Limited Production of an immunogen using a plant virus
TWI641382B (zh) * 2013-01-31 2018-11-21 韓美藥品股份有限公司 於包含因子ｖｉｉ之組成物中使病毒失活之方法
CN104043120B (zh) 2013-03-13 2017-05-31 南京赛威信生物医药有限公司 乙型肝炎疫苗
US10279019B2 (en) 2014-02-11 2019-05-07 Stc.Unm PCSK9 peptide vaccine conjugated to a Qbeta carrier and methods of using the same
WO2015128287A1 (en) 2014-02-28 2015-09-03 Affiris Ag Pcsk9 vaccines
CN104558199B (zh) * 2014-09-05 2018-07-06 成都康弘生物科技有限公司 一种治疗高胆固醇血症的融合蛋白制备及其用途
US20180066070A1 (en) * 2015-02-18 2018-03-08 Universitat Zurich Acetylated pcsk9
TWI655002B (zh) * 2015-07-20 2019-04-01 碩騰服務有限責任公司 脂質體佐劑組合物
WO2017068482A1 (en) 2015-10-19 2017-04-27 Cadila Healthcare Limited New adjuvant and vaccine composition containing the same
RU2734924C2 (ru) * 2015-11-03 2020-10-26 Аффирис Аг Способ вакцинации против аутоантигена у пациента-человека
CA3018482A1 (en) * 2016-03-25 2017-09-28 Osaka University Conjugate vaccine targeting a disease-causing biological protein
AU2017281332A1 (en) * 2016-06-24 2018-12-20 F. Hoffmann-La Roche Ag Compositions and methods for treating cardiovascular disease
CN106822881A (zh) * 2016-12-09 2017-06-13 四川大学 一种针对pcsk9的抗高血脂蛋白疫苗
BR112019020148A2 (pt) * 2017-04-13 2020-05-05 Cadila Healthcare Ltd peptídeo
CN107488215A (zh) * 2017-07-19 2017-12-19 邱志华 人前蛋白转化酶枯草溶菌素9免疫原性肽段及其载体疫苗
EP3826623A4 (en) 2018-06-25 2022-03-23 Duke University COMPOSITIONS AND METHODS FOR TREATING CANCER CHARACTERIZED BY PCSK9 EXPRESSION
US20220380425A1 (en) * 2019-07-04 2022-12-01 Cadila Healthcare Limited Angptl3 based vaccine for the treatment of liver disease
WO2021154947A1 (en) * 2020-01-28 2021-08-05 Ubi Ip Holdings Peptide immunogens targeting pcsk9 and formulations thereof for prevention and treatment of pcsk9-mediated disorders
JP2023515908A (ja) 2020-03-01 2023-04-14 ヴァルネヴァ・オーストリア・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ＣｐＧアジュバント化ＳＡＲＳ－ＣｏＶ－２ウイルスワクチン
WO2021178306A1 (en) 2020-03-01 2021-09-10 Dynavax Technologies Corporation Coronavirus vaccines comprising a tlr9 agonist
WO2022147373A1 (en) * 2020-12-31 2022-07-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
KR20240153599A (ko) 2022-02-28 2024-10-23 트리뎀 바이오사이언스 게엠베하 & 씨오 케이지 적어도 β-글루칸 또는 만난으로 구성되거나 또는 이를 포함하는 접합체
CN117327159A (zh) * 2023-07-31 2024-01-02 杭州纽龙生物科技有限公司 一种蛋白a耐碱突变方法
US12502428B1 (en) 2025-04-30 2025-12-23 Utopia Therapeutics Pvt Ltd. Immunotherapeutic composition for prevention of obesity, nonalcoholic fatty liver disease and hypertriglyceridemia, and methods of use and preparation thereof
CN120647779B (zh) * 2025-08-20 2025-12-02 广州千扬生物医药技术有限公司 一种蛋白纳米颗粒及其组合物在制备防治肿瘤的药物中的应用

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773946A (en) 1969-09-02 1973-11-20 Parke Davis & Co Triglyceride-lowering compositions and methods
US3930024A (en) 1969-09-02 1975-12-30 Parke Davis & Co Pharmaceutical compositions and methods
JPS5522636A (en) 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
WO1980000727A1 (en) 1978-09-29 1980-04-17 Secretary Energy Brit Improvements in and relating to electrical power transmission in fluid wells
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
AU548727B2 (en) 1981-03-12 1986-01-02 Gruppo Lepetit S.P.A. Beta-lactam acetic acid derivatives
AU568067B2 (en) 1981-10-23 1987-12-17 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and methods of making same
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
IL64542A0 (en) 1981-12-15 1982-03-31 Yissum Res Dev Co Long-chain alpha,omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them
JPS60136512A (ja) 1983-12-26 1985-07-20 Eisai Co Ltd 脂質代謝改善剤
DE3423166A1 (de) 1984-06-22 1986-01-02 Epis S.A., Zug Alpha-, omega-dicarbonsaeuren, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten
US4722840A (en) 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
US5374426A (en) 1986-09-03 1994-12-20 University Of Saskatchewan Rotavirus nucleocapsid protein VP6 in vaccine compositions
US4950740A (en) 1987-03-17 1990-08-21 Cetus Corporation Recombinant diphtheria vaccines
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
CA2006700A1 (en) 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
FI920131A7 (fi) 1989-07-14 1992-01-13 American Cyanamid Co Sytokiini- ja hormonikantajia konjugaattirokotteita varten
NZ235315A (en) 1989-09-19 1991-09-25 Wellcome Found Chimaeric hepadnavirus core antigen proteins and their construction
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
JP2999579B2 (ja) 1990-07-18 2000-01-17 武田薬品工業株式会社 Ｄｎａおよびその用途
DE69113564T2 (de) 1990-08-13 1996-05-30 American Cyanamid Co Faser-Hemagglutinin von Bordetella pertussis als Träger für konjugierten Impfstoff.
AU9052091A (en) 1990-12-20 1992-07-22 Smithkline Beecham Biologicals (Sa) Vaccines based on hepatitis b surface antigen
DE4202394A1 (de) 1991-04-04 1992-10-08 Teves Gmbh Alfred Schwimmsattel-teilbelagscheibenbremse mit einem bremsengehaeuse aus leichtmetall
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
WO1993021769A1 (en) 1992-05-06 1993-11-11 President And Fellows Of Harvard College Diphtheria toxin receptor-binding region
KR100278157B1 (ko) 1992-06-25 2001-01-15 장 스테판느 보조약을 함유하는 백신 조성물
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
CZ289476B6 (cs) 1993-03-23 2002-01-16 Smithkline Beecham Biologicals (S.A.) Očkovací přípravek a způsob jeho výroby
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
CA2194761C (en) 1994-07-15 2006-12-19 Arthur M. Krieg Immunomodulatory oligonucleotides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5648387A (en) 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
CN1185811A (zh) 1995-03-31 1998-06-24 H·沃尔夫 依赖于逆转录病毒样颗粒的抗原呈递系统
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
US6610661B1 (en) 1996-10-11 2003-08-26 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
IL119971A (en) 1997-01-07 2003-02-12 Yissum Res Dev Co Pharmaceutical compositions containing dicarboxylic acids and derivatives thereof and some novel dicarboxylic acids
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
JP2001513776A (ja) 1997-02-28 2001-09-04 ユニバーシティ オブ アイオワ リサーチ ファウンデーション ＬＰＳ関連障害の処置における非メチル化ＣｐＧジヌクレオチドを含む核酸の使用
JP5087758B2 (ja) 1997-03-10 2012-12-05 オタワ ホスピタル リサーチ インスティチュート アジュバントとして非メチル化ＣｐＧジヌクレオチドを含む核酸の使用
ATE370740T1 (de) 1997-05-20 2007-09-15 Ottawa Health Research Inst Verfahren zur herstellung von nukleinsäurekonstrukten
AU753172B2 (en) 1997-06-06 2002-10-10 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
IL121165A0 (en) 1997-06-26 1997-11-20 Yissum Res Dev Co Pharmaceutical compositions containing carboxylic acids and derivatives thereof
DE69838992T2 (de) 1997-09-05 2008-12-24 Glaxosmithkline Biologicals S.A., Rixensart Öl-in-Wasser Emulsionen mit Saponinen
CN100387622C (zh) 1998-02-12 2008-05-14 免疫合成物公司 策略性修饰的乙肝核心蛋白及其衍生物
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
ATE356630T1 (de) 1998-04-03 2007-04-15 Univ Iowa Res Found Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine
AU746163B2 (en) 1998-04-09 2002-04-18 Smithkline Beecham Biologicals (Sa) Adjuvant compositions
TWI227241B (en) * 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
EP1114024B1 (de) 1998-09-18 2002-11-27 Pentapharm A.G. Urokinase-inhibitoren
WO2000021478A1 (en) 1998-09-28 2000-04-20 Hans Balle Aps Lift, preferably for seats on wheelchairs
US6203837B1 (en) 1998-10-06 2001-03-20 Xcafe' Llc Coffee system
SI1126876T1 (sl) 1998-10-16 2007-08-31 Glaxosmithkline Biolog Sa Adjuvantni sistemi in vakcine
JP4486257B2 (ja) 1998-10-21 2010-06-23 アメリカ合衆国 自己抗体の誘導のためのウイルス様粒子
JP2002528123A (ja) 1998-11-05 2002-09-03 パウダージェクト ヴァクシンズ，インコーポレイテッド 遺伝子免疫のための核酸構築物
RU2245163C2 (ru) 1998-11-30 2005-01-27 Сайтос Байотекнолэджи АГ Композиция (варианты), способ получения не природной упорядоченной и содержащей повторы антигенной матрицы, способ терапевтического лечения и способ иммунизации
JP4689044B2 (ja) 1998-12-21 2011-05-25 メディミューン，インコーポレーテッド ワクチン用の肺炎連鎖球菌タンパク質と免疫原断片
KR100802198B1 (ko) 1998-12-23 2008-02-11 샤이어 바이오켐 인코포레이티드 신규한 스트렙토코커스 항원
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
EP2204186B1 (en) 1999-02-17 2016-04-06 CSL Limited Immunogenic complexes and methods relating thereto
HU229968B1 (hu) * 1999-03-19 2015-03-30 Smithkline Beecham Biologicals S.A Sztreptokokkusz oltóanyag
IL145712A0 (en) 1999-04-01 2002-07-25 Esperion Therapeutics Inc Ether compounds, compositions, and uses thereof
WO2000061761A2 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
GB9908533D0 (en) 1999-04-14 1999-06-09 Novartis Ag Organic compounds
HK1044484B (en) 1999-04-19 2005-07-29 Smithkline Beecham Biologicals S.A. Adjuvant composition containing saponin and immunostimulatory oligonucleotide
NO309798B1 (no) * 1999-04-30 2001-04-02 Targovax As Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen
AU765824B2 (en) 1999-09-24 2003-10-02 Smithkline Beecham Biologicals (Sa) Vaccines
CO5200838A1 (es) 1999-09-24 2002-09-27 Smithkline Beecham Corp Vacunas
WO2001022990A2 (en) 1999-09-27 2001-04-05 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
CN100360556C (zh) 2000-04-07 2008-01-09 利兹创新有限公司大学 乙型肝炎核心抗原的融合蛋白
EP1278542A2 (en) 2000-05-05 2003-01-29 Cytos Biotechnology AG Molecular antigen arrays and vaccines
JP5051959B2 (ja) 2000-06-20 2012-10-17 アイディー バイオメディカル コーポレイション オブ ケベック ストレプトコッカス抗原
JP2004500868A (ja) 2000-06-22 2004-01-15 セルテック　ファーマスーティカルズ　リミテッド Ｂ型肝炎コア抗原の修飾
WO2002005690A1 (en) 2000-07-15 2002-01-24 Lighthouse Display International Limited Shelf edge display fittings
GB0121171D0 (en) * 2001-08-31 2001-10-24 Glaxosmithkline Biolog Sa Vaccine
AUPQ912000A0 (en) 2000-07-31 2000-08-24 Crown In The Right Of The Queensland Department Of Health, The Improved virus like particles
US20030138769A1 (en) 2000-08-16 2003-07-24 Birkett Ashley J. Immunogenic HBc chimer particles having enhanced stability
US7264810B2 (en) 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
AU2002309706A1 (en) 2001-05-11 2002-11-25 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
JP4516748B2 (ja) * 2001-09-14 2010-08-04 サイトス バイオテクノロジー アーゲー ウィルス様粒子中への免疫賦活物質のパッケージ化：調製法および使用法
AU2002347404A1 (en) 2001-09-14 2003-04-01 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
JP4671389B2 (ja) 2001-10-05 2011-04-13 サイトス バイオテクノロジー アーゲー アンジオテンシンペプチド−担体複合体およびその使用
AU2002351623A1 (en) 2001-12-20 2003-07-09 Shire Biochem Inc. Streptococcus antigens
EP1517702A4 (en) 2002-02-21 2006-05-03 Apovia Inc IMMUNOGENIC HBC CHIMERIC PARTICLES STABILIZED WITH AN N-TERMINAL END CYSTEINE
GB0209878D0 (en) 2002-04-30 2002-06-05 Glaxosmithkline Biolog Sa Vaccine
CN102061288A (zh) * 2002-07-17 2011-05-18 希托斯生物技术股份公司 使用衍生自ap205外壳蛋白的病毒样颗粒的分子抗原阵列
GB0219524D0 (en) * 2002-08-21 2002-10-02 Queen Mary & Westfield College Therapeutic uses of monoclonal antibodies to the angiotensin-II type-1 receptor
AU2003300841B2 (en) 2002-12-10 2008-03-20 Lorantis Ltd. Stabilized immunogenic HBc chimer particles
CN101818185B (zh) 2003-03-13 2016-05-25 葛兰素史密丝克莱恩生物有限公司 纯化细菌溶细胞素的方法
EP1471152A1 (en) 2003-04-25 2004-10-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Mutations in the human PCSK9 gene associated to hypercholesterolemia
JP2008506789A (ja) 2004-07-18 2008-03-06 シーエスエル、リミテッド インターフェロン−ガンマ応答強化を誘発するための免疫刺激複合体及びオリゴヌクレオチド処方物
EP1776105A2 (en) 2004-07-18 2007-04-25 Coley Pharmaceutical Group, Ltd Methods and compositions for inducing innate immune responses
GB0421083D0 (en) 2004-09-22 2004-10-27 Glaxosmithkline Biolog Sa Purification process
EP1736538A1 (en) 2005-06-21 2006-12-27 Cytos Biotechnology AG Process for the preparative purification of virus-like-particles (VLPs)
ES2526879T3 (es) 2006-02-15 2015-01-16 Adiutide Pharmaceuticals Gmbh Composiciones y procedimientos para formulaciones de oligonucleótidos
EP2021467A4 (en) * 2006-05-08 2010-01-20 Adaerata Ltd Partnership CHIMERIC PCSK9 PROTEINS, THESE INCLUDING CELLS AND TEST METHODS THEREWITH
US7572618B2 (en) * 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
US20080166785A1 (en) 2006-08-16 2008-07-10 Monica Sala-Schaeffer Polynucleotides allowing the expression and secretion of recombinant HBsAg virus-like particles containing a foreign peptide, their production and use
CA2680832A1 (en) * 2007-03-27 2008-10-02 Merck & Co., Inc. Method for detecting autoprocessed, secreted pcsk9
US20100233177A1 (en) * 2007-04-13 2010-09-16 David Langdon Yowe Molecules and methods for modulating proprotein convertase subtilisin/kexin type 9 (pcsk9)
US20100183662A1 (en) 2007-06-26 2010-07-22 Ralph Leon Biemans Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
JOP20080381B1 (ar) * 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
US8598320B2 (en) * 2007-10-26 2013-12-03 Merck Sharp & Dohme Corp. Anti-PCSK9 and methods for treating lipid and cholesterol disorders
WO2009080823A2 (en) * 2007-12-20 2009-07-02 Cytos Biotechnology Ag Nerve growth factor conjugates and uses thereof
AR070315A1 (es) * 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
AR070316A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
TWI516501B (zh) * 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
AT507604A1 (de) 2008-11-19 2010-06-15 Affiris Forschungs & Entwicklungs Gmbh Behandlung von atherosklerose
US9501570B2 (en) 2014-07-14 2016-11-22 Verizon Patent And Licensing Inc. Dynamic routing system
US9719791B2 (en) 2014-12-10 2017-08-01 Mapquest, Inc. Computerized systems and methods for providing travel information and/or content to users
US11780237B2 (en) 2015-06-23 2023-10-10 Ripples Ltd Method and apparatus for printing on a drink
US10114918B2 (en) 2016-01-27 2018-10-30 Arm Limited Physical placement control for an integrated circuit based on state bounds file

Also Published As

Publication number Publication date
CN102612558B (zh) 2015-02-11
KR20140004263A (ko) 2014-01-10
SA114350178B1 (ar) 2017-03-05
SA114350179B1 (ar) 2016-03-01
EP3358008A1 (en) 2018-08-08
IL254600A0 (en) 2017-11-30
AR078247A1 (es) 2011-10-26
KR101660577B1 (ko) 2016-09-27
HK1209619A1 (en) 2016-04-08
NZ599059A (en) 2014-05-30
KR20120089451A (ko) 2012-08-10
EP2473605A2 (en) 2012-07-11
US20150098957A1 (en) 2015-04-09
WO2011027257A3 (en) 2011-06-30
JP2018039821A (ja) 2018-03-15
US9481875B2 (en) 2016-11-01
SA110310687B1 (ar) 2014-10-16
CN104548089B (zh) 2017-09-26
NZ620441A (en) 2015-08-28
US20110052621A1 (en) 2011-03-03
AR107020A2 (es) 2018-03-14
AU2010290931B2 (en) 2014-02-06
CO6501190A2 (es) 2012-08-15
RU2012107657A (ru) 2013-10-10
CN104587462A (zh) 2015-05-06
SG178447A1 (en) 2012-03-29
RU2014143531A3 (es) 2018-06-22
EP2473605B1 (en) 2018-04-11
PL2473605T3 (pl) 2018-08-31
TW201113035A (en) 2011-04-16
SI2473605T1 (en) 2018-06-29
US9987341B2 (en) 2018-06-05
RU2538162C2 (ru) 2015-01-10
IL218229A0 (en) 2012-04-30
CA2771770A1 (en) 2011-03-10
US20170100467A1 (en) 2017-04-13
EP2865752A1 (en) 2015-04-29
SG10201401515YA (en) 2014-08-28
NO2473605T3 (es) 2018-09-08
BR112012004807A2 (pt) 2017-04-11
US20180318407A1 (en) 2018-11-08
AU2010290931A1 (en) 2012-03-29
JP2017039748A (ja) 2017-02-23
JP5859150B2 (ja) 2016-02-10
PT2473605T (pt) 2018-05-28
WO2011027257A2 (en) 2011-03-10
KR101660578B1 (ko) 2016-09-27
CN102612558A (zh) 2012-07-25
CN104548089A (zh) 2015-04-29
KR101512053B1 (ko) 2015-04-28
US8889144B2 (en) 2014-11-18
HK1174056A1 (en) 2013-05-31
JP2016106089A (ja) 2016-06-16
JP2015131814A (ja) 2015-07-23
JP2013503623A (ja) 2013-02-04
DK2473605T3 (en) 2018-05-28
TR201808222T4 (tr) 2018-07-23
ES2670576T3 (es) 2018-05-31
MY163512A (en) 2017-09-15
CA2846746A1 (en) 2011-03-10
RU2014143531A (ru) 2016-05-20
HUE037416T2 (hu) 2018-08-28
IL218229A (en) 2017-10-31
PH12016500004A1 (en) 2016-12-05
PH12016500040A1 (en) 2016-12-05
CN104587462B (zh) 2017-09-26
KR20140007500A (ko) 2014-01-17
SG10201401516XA (en) 2014-10-30
PE20161551A1 (es) 2017-01-18
NZ710626A (en) 2017-03-31
MX2012002639A (es) 2012-03-14
TWI400085B (zh) 2013-07-01
PE20161560A1 (es) 2017-01-11
HK1208346A1 (zh) 2016-03-04

Similar Documents

Publication Publication Date Title
PE20121544A1 (es) Vacuna de pcsk9
ES2563646T3 (es) Composiciones y métodos relacionados con variantes de la proteína A (SpA)
PE20141210A1 (es) Mutantes de la polimerasa de hbv
AR067972A1 (es) Composiciones de fenilalaninamoniacoliasa de procariontes y uso de sus composiciones en metodos para tratar cancer
PE20100658A1 (es) COMPOSICION INMUNOGENICA QUE COMPRENDE gE VZV Y UN ADYUVANTE QUE CONTIENE QS21, COLESTEROL Y 3D-MPL
PH12015501637A1 (en) Inactivated dengue virus vaccine with aluminium-free adjuvant
ES2585328T3 (es) Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis
PE20142330A1 (es) Vacuna de peptido ch3 de ige
PE20141296A1 (es) Composiciones y metodos para tratar el virus de la hepatitis c
CO6511229A2 (es) Metodos para reducir la actividad viricida en composiciones pcv-2 y composiciones pcv-2 con una inmunogeicidad mejorada
DK2459216T3 (da) Immunogene sammensætninger omfattende tlr-aktivitetsmodulatorer
MX337028B (es) Eliminacion de serina proteasas por tratamiento con dioxido de silicona finamente dividido.
NZ628756A (en) Immunogens for hiv vaccination
PE20170301A1 (es) Medios y metodos para el tratamiento cmv
WO2009152147A3 (en) Compositions and methods for dengue virus (dv) treatment and vaccination
PE20120324A1 (es) Combinacion que comprende (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y donezepilo como moduladora de trastornos cognitivos
AR079941A2 (es) Organismos clostridium atenuados recombinados y vacuna
CL2009000803A1 (es) Uso de una variante de igf-1 pegilada para tratar, prevenir un trastorno neuromuscular; metodo para el tratamiento, prevencion y/o demora de un trastorno neuromuscular; composicion que comprende la variante de igf-1 modificada
AR089618A1 (es) Composiciones detergentes
PE20110106A1 (es) Peptidos mediadores del eflujo del colesterol mejorados
AR101871A1 (es) Composiciones de glicoconjugado inmunogénico / terapéutico y sus usos
AR095076A1 (es) Péptidos y composiciones para el tratamiento de daño articular
NZ594268A (en) Grass peptides for vaccine
NI201700080A (es) Composiciones de vacuna para el virus del dengue y métodos de uso de las mismas.
DE60336588D1 (de) Verbesserte anthraximpfstoffe und abgabeverfahren

Legal Events

Date Code Title Description
FG Grant, registration